Literature DB >> 10825335

Absorbents differ enormously in their capacity to produce compound A and carbon monoxide.

C R Stabernack1, R Brown, M J Laster, R Dudziak, E I Eger.   

Abstract

UNLABELLED: Concern persists regarding the production of carbon monoxide (CO) and Compound A from the action of carbon dioxide (CO(2)) absorbents on desflurane and sevoflurane, respectively. We tested the capacity of eight different absorbents with various base compositions to produce CO and Compound A. We delivered desflurane through desiccated absorbents, and sevoflurane through desiccated and moist absorbents, then measured the resulting concentrations of CO from the former and Compound A from the latter. We also tested the CO(2) absorbing capacity of each absorbent by using a model anesthetic system. We found that the presence of potassium hydroxide (KOH) and sodium hydroxide (NaOH) increased the production of CO from calcium hydroxide (Ca[OH](2)) but did not consistently affect production of Compound A. However, the effect of KOH versus NaOH was not consistent in its impact on CO production. Furthermore, the effect of KOH versus NaOH versus Ca(OH)(2) was inconsistent in its impact on Compound A production. Two absorbents (Amsorb) [Armstrong Medica, Ltd, Coleraine, Northern Ireland], composed of Ca(OH)(2) plus 0.7% polyvinylpyrrolidine, calcium chloride, and calcium sulfate; and lithium hydroxide) produced dramatically lower concentrations of both CO and Compound A. Both produced minimal to no CO and only small concentrations of Compound A. The presence of polyvinylpyrrolidine, calcium chloride, and calcium sulfate in Amsorb appears to have suppressed the production of toxic products. All absorbents had an adequate CO(2) absorbing capacity greatest with lithium hydroxide. IMPLICATIONS: Production of the toxic substances, carbon monoxide and Compound A, from anesthetic degradation by carbon dioxide absorbents, might be minimized by the use of one of two specific absorbents, Amsorb (Armstrong Medica, Ltd., Coleraine, Northern Ireland) (calcium hydroxide which also includes 0.7% polyvinylpyrrolidine, calcium chloride, and calcium sulfate) or lithium hydroxide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825335     DOI: 10.1097/00000539-200006000-00033

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

Review 1.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Detection of carbon monoxide production as a result of the interaction of five volatile anesthetics and desiccated sodalime with an electrochemical carbon monoxide sensor in an anesthetic circuit compared to gas chromatography.

Authors:  Christiaan Keijzer; Roberto S G M Perez; Jaap J de Lange
Journal:  J Clin Monit Comput       Date:  2007-06-28       Impact factor: 2.502

3.  Comparison of the renal safety between carbon dioxide absorbent products under sevoflurane anesthesia: a pilot study.

Authors:  Hyung-Chul Lee; Donguk Kim; Wonsik Ahn; Jiyeon Sim; Yehoon Chung
Journal:  Korean J Anesthesiol       Date:  2012-07-24

4.  Carbon monoxide production from five volatile anesthetics in dry sodalime in a patient model: halothane and sevoflurane do produce carbon monoxide; temperature is a poor predictor of carbon monoxide production.

Authors:  Christiaan Keijzer; Roberto Sgm Perez; Jaap J De Lange
Journal:  BMC Anesthesiol       Date:  2005-06-02       Impact factor: 2.217

Review 5.  Sevoflurane.

Authors:  Stefan De Hert; Anneliese Moerman
Journal:  F1000Res       Date:  2015-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.